Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Early IL-2 treatment of mice with Pseudomonas aeruginosa pneumonia induced PMN-dominating response and reduced lung pathology

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Nephrotic syndrome and pulmonary hypertension as complications of intravenous drug abuse

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The environmental occurrence of Pseudomonas aeruginosa

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Analysis of proximal bone margins in diabetic foot osteomyelitis by conventional culture, DNA sequencing and microscopy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. L-serine: a neglected amino acid with a potential therapeutic role in diabetes

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

IL-2 is a pro-inflammatory and a Th1 inducing cytokine, which is important for activation of the cell-mediated immunity. IL-2 in serum and sputum has been observed to be reduced in cystic fibrosis (CF) patients. The present IL-2 treatment study of Pseudomonas aeruginosa (PA) lung infected mice was performed in order to evaluate the effect of IL-2 supplement. One hundred-and-twenty female BALB/c mice were divided into three groups: 1) IL-2 treatment/infection (TIG), 2) non-treatment/infection (NTIG), and 3) IL-2 treatment/non-infection (TNIG). The mice were challenged intra-tracheally with PA (PAO579) embedded in seaweed alginate to resemble the biofilm mode of growth. At day 0 and 1, the treatment groups received IL-2 s.c. Mice were killed on day 1 or 2, and cytokine production, lung pathology, and quantitative lung bacteriology were estimated. IL-2 treatment of infected mice reduced the number of mice with signs of macroscopic lung pathology at day 2 (p < 0.05). The reduced macroscopic pathology was paralleled by a reduced IL-1β and TNF-α. In contrast, an increased PMN response at day 2 was observed in the IL-2 treated mice (p < 0.01). This was preceded by a significantly higher degree of microscopic inflammation at day 1 (p < 0.02). The IL-12 levels decreased in both groups of infected mice at day 2 (p < 0.01), however, significantly more in the IL-2 treated mice (p < 0.02). In accordance, but surprisingly, IFN-γ was significantly reduced in the IL-2 treated PA infected group at day 2 (p < 0.05). The present results indicate that early IL-2 treatment prolongs the PMN response but also reduces pro-inflammatory IL-1β and TNF-α and macroscopic signs of pathology.

Original languageEnglish
JournalAPMIS - Journal of Pathology, Microbiology and Immunology
Volume128
Issue number12
Pages (from-to)647-653
Number of pages7
ISSN0903-4641
DOIs
Publication statusPublished - Dec 2020

Bibliographical note

© 2020 Scandinavian Societies for Medical Microbiology and Pathology.

    Research areas

  • Cystic fibrosis, IL-2, lung infection, Pseudomonas aeruginosa, Th1/Th2 response

ID: 60681122